These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. Nseyo UO; Shumaker B; Klein EA; Sutherland K J Urol; 1998 Jul; 160(1):39-44. PubMed ID: 9628601 [TBL] [Abstract][Full Text] [Related]
51. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139 [TBL] [Abstract][Full Text] [Related]
52. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986 [TBL] [Abstract][Full Text] [Related]
54. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187 [TBL] [Abstract][Full Text] [Related]
55. Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. de Jong JJ; Hendricksen K; Rosier M; Mostafid H; Boormans JL Bladder Cancer; 2018 Oct; 4(4):395-401. PubMed ID: 30417050 [TBL] [Abstract][Full Text] [Related]
56. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. Matulay JT; Li R; Hensley PJ; Brooks NA; Narayan VM; Grossman HB; Navai N; Dinney CPN; Kamat AM J Urol; 2021 Jun; 205(6):1612-1621. PubMed ID: 33502236 [TBL] [Abstract][Full Text] [Related]
57. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer]. Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710 [TBL] [Abstract][Full Text] [Related]
58. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected? Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379 [TBL] [Abstract][Full Text] [Related]
59. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149 [TBL] [Abstract][Full Text] [Related]
60. Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study. Nishiyama N; Kitamura H; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Masumori N Jpn J Clin Oncol; 2014 Nov; 44(11):1101-8. PubMed ID: 25139163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]